A Phase III trial showed a significant overall survival benefit of 63.9 months with ribociclib, compared to 51.4 months with hormone therapy alone. The estimated six-year survival rate was 44.2% with ribociclib, compared to 32% for placebo.
A new study suggests that age does not negatively impact on survival benefit from immune checkpoint inhibitors in elderly patients with stage IV NSCLC. Patients aged 75 and older showed a significant survival benefit from ICIs compared to younger patients.
Researchers found that pre-treatment circulating tumor DNA (ctDNA) levels can accurately predict long-term survival in non-small cell lung cancer (NSCLC) patients. Patients with low ctDNA levels had significantly improved progression-free survival and overall survival compared to those with high levels.
The Phase III POSEIDON trial demonstrated a statistically significant improvement in progression-free survival and overall survival for patients with metastatic non-small cell lung cancer (mNSCLC) treated with chemotherapy plus durvalumab and tremelimumab. Durvalumab combined with tremelimumab and chemotherapy reduced the risk of death...
The IMpower010 trial found significant disease-free survival improvement in patients with resected stage II-IIIA non-small cell lung cancer treated with atezolizumab. The study showed a benefit across different disease stages, surgery types, and chemotherapy regimens.
Ongoing acute kidney injury in deceased donor kidneys is linked to lower long-term graft survival. Notably, abnormal serum creatinine values during procurement also negatively impact graft outcomes.
A significant association was found between statin use and improved outcomes in women with stage I-III triple-negative breast cancer. Statin use was associated with a 58% relative improvement in breast cancer-specific survival and a 30% relative improvement in overall survival.
A new study found that obese patients with advanced prostate cancer survive longer than their overweight and normal-weight counterparts. Obesity was associated with a 10% higher survival rate over 36 months. The 'obesity paradox' suggests that high body mass index may be protective in certain cases.
Research identifies two critical thresholds for stream flow and salmon survival, with a historic mean flow of 10,712 cfs providing an important target for managing water resources. Enacting flows to match this threshold could increase salmon survival rates by doubling or tripling in some years.
A meta-analysis of 106 RCTs found psychosocial interventions prolonging life by 20% compared to standard care. Interventions promoting health behaviors were associated with improved survival, while those focusing solely on emotional support yielded smaller gains.
A new study found that leaving an atrial communication at biventricular repair of unbalanced AVSD is associated with reduced long-term survival. The study included 581 patients and showed a significant difference in five-year survival rates between those with and without atrial fenestration.
A new study reveals that higher body mass index (BMI) is associated with worse survival in early breast cancer patients but improved survival in advanced disease. The 'obesity paradox' highlights the need to understand the biological basis of obesity impacts on breast cancer diagnosis and treatment.
A UT Southwestern Medical Center review of Texas Cancer Registry data found that Black and Hispanic patients under 40 with cancer have lower survival rates compared to their white counterparts. The study also showed that poverty and lack of insurance coverage exacerbate these disparities.
A new study suggests that long-term survival data for immunotherapies should be re-analyzed for potential misinterpretation. Researchers propose an adjustment method, Cox-TEL, to correct inaccurate results based on the Cox proportional-hazards model.
A recent study by Yale Cancer Center reveals that young patients with early-onset colorectal cancer (under age 50) have a better survival rate than those diagnosed at older ages. After adjusting for stage at diagnosis, these patients had a 5% lower risk of death compared to those diagnosed between 51-55 years old.
Researchers at WashU Medicine found that administering chemotherapy drug temozolomide in the morning improved overall survival by about 4 months compared to evening, with an average increase of 3.5 months in patients with MGMT methylated tumors. The study suggests that adjusting timing of standard treatment could enhance effectiveness.
Advanced liver fibrosis worsens cancer-specific and overall survival in iCCA patients, regardless of surgical resection. Patients with advanced fibrosis are at increased risk of mortality across follow-up periods.
A phase III randomized study found that lenvatinib plus pembrolizumab significantly prolonged survival in patients with advanced kidney cancer. Treatment combinations showed improved progression-free and overall survival rates compared to sunitinib.
The combination of lenvatinib and pembrolizumab significantly improved overall survival, progression-free survival, and response rates compared to sunitinib in untreated patients with metastatic kidney cancer. The study results demonstrate the importance of immune checkpoint inhibitors in first-line treatment.
Researchers at UCLA Jonsson Comprehensive Cancer Center identified a new approach combining an anti-psychotic drug, a statin and radiation to improve overall survival in mice with glioblastoma. The triple combination extended median survival 4-fold compared to radiation alone, providing hope for improved treatment options.
The IMbrave150 trial found that the atezo+bev combination provided a median overall survival of 19.2 months, surpassing the 13.4-month median for those treated with sorafenib alone. The treatment also showed improved survival rates at 18 months, with 52% of patients on atezo+bev remaining alive compared to 40% on sorafenib.
The Phase 3 clinical trial showed a 30% improvement in survival for patients over 55 with AML. The drug, CC-486, significantly improved survival without impacting quality of life.
A new study from the University of Pennsylvania School of Nursing found that better medical-surgical nurse staffing has a greater effect on black patients than white patients, and differences in survival to discharge after an IHCA are more pronounced in poorly staffed hospitals. The study included over 14,000 patients in 75 US hospitals.
The study compared survival rates in patients undergoing surgery for brain metastases with conventional white light microscopy versus 5-ALA fluorescence microscopy. The results showed no significant difference in local recurrence or mortality between the two groups, but radiotherapy was strongly associated with improved survival.
A new study published in Frontiers In Oncology found a negative association between beta-blocker use and survival outcomes in patients with HER2 positive advanced breast cancer. The research highlights a subgroup of patients whose survival outcomes are poorer and calls for further investigation to improve treatment outcomes.
A clinical trial found that patients with IDH-mutant high-risk LGG, regardless of codeletion status, receive a survival benefit from adding postradiation chemotherapy. The study supports the use of WHO-defined molecular subgroups in predicting response to treatment.
Research from the University of Montana found that tropical songbirds reduce reproduction during severe droughts, but this shift actually increases their survival rates. Long-lived species experience higher survival rates during drought years than non-drought years.
Researchers developed a tumour gene test that accurately predicts ovarian cancer survival, outperforming age and cancer stage. The test identifies high-risk patients for personalized treatment options.
Researchers found that climate change positively impacts yellow-bellied marmot survival during short, wet summers and negatively affects it during harsh winters. This study suggests that certain species may benefit in one season while facing unfavorable conditions in another due to climate change.
A study by researchers at Karolinska Institutet found a significant association between income and survival after surgery for lung cancer. Patients with low household disposable income had significantly worse long-term survival compared to those with high income, even after adjusting for common comorbidities.
Researchers identified a type of cell fusion between cancer cells and white blood cells called tumor-macrophage fusion (TMF), where the size and number of TMFs may predict disease-free survival. Larger TMFs were linked to shorter disease-free survival rates.
Researchers found that COVID-19 patients' survival rates after resuscitation vary greatly, with probabilities ranging from less than 3% to over 22%. Younger patients with shockable rhythms had higher survival rates without severe neurological disability.
Researchers at Mayo Clinic have found that combining density of immune cells with analysis of tumor budding can improve accuracy in predicting patient survival for patients with stage III colon cancer. This method provides important data on patient survival and may lead to personalized treatment recommendations.
Researchers at Yale Cancer Center discovered that a small amount of the PD-L1 biomarker can predict long-term survival benefits from using pembrolizumab in patients with advanced lung cancer. The study found that overall survival was about 99% one year after discontinuing treatment, and ranged from 23% to 35% three years after treatment.
Survival rates have improved significantly for children who received kidney transplants, with a 72% lower mortality risk among those transplanted later than earlier periods. This improvement is primarily attributed to reduced deaths from cardiovascular causes and infections.
A recent study published in Blood Advances eliminates BCL-W as a potential therapeutic target for B cell lymphomas. The research team used gene editing technology and demonstrated that human B cell lymphoma cell lines can survive without BCL-W, contradicting earlier speculation about its role in cancer survival.
A phase 3 study showed that combining PD-L1 inhibitor atezolizumab and VEGF inhibitor bevacizumab significantly improved overall survival and progression-free survival in patients with unresectable HCC. The treatment combination also increased overall response rate and delayed deterioration in quality of life.
Researchers have discovered that blocking MCL1 protein can eliminate melanoma cells more effectively, even in late-stage cancers. Combining MCL1 antagonist AZD5991 with existing treatments like vemurafenib has a 'double whammy' effect against cancer cells.
Analysis of US heart transplant data reveals large discrepancies in how sick patients are when they receive transplants at different hospitals. The study finds that high-survival-benefit hospitals prioritize sicker patients, while low-survival-benefit centers give organs to less critical patients.
First-line osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non-small cell lung cancer. The median overall survival with osimertinib was 38.6 months, with over half of patients alive at three years.
A study of nearly 1.9 million breast cancer patients found that men have lower three-year and five-year survival rates compared to women. The analysis attributed the difference to undertreatment and clinical characteristics.
Survival rates for seven cancers have improved in Australia, Canada, and Norway compared to New Zealand, Denmark, Ireland, and the UK. The largest gains were seen in patients under 75 years old with poor prognosis cancers. Improvements in cancer control suggest progress has been made in these countries.
Cancer survival in the UK has improved since 1995, with significant increases in one-year and five-year survival rates for various cancers. Despite this progress, the UK still lags behind other high-income countries in cancer survival.
Patients taking nivolumab experience a significant five-fold increase in overall survival, with five-year rates of 13.4% compared to docetaxel's 2.6%. Long-term benefits and improved progression-free survival have been observed with nivolumab treatment.
The KEYNOTE-024 trial found that pembrolizumab significantly improved progression-free and overall survival in patients with advanced non-small-cell lung cancer. Patients treated with pembrolizumab had a median overall survival of 26.3 months compared to 14.2 months for those on chemotherapy.
The Impower131 Trial found that atezolizumab + chemotherapy improved overall survival by 3.9 months compared to chemotherapy alone, particularly among patients with high PD-L1 expression. Treatment-related side effects were common but manageable in both arms.
Durvalumab plus chemotherapy significantly improved overall survival in patients with extensive-stage small cell lung cancer, with a median survival of 13 months compared to 10.3 months for the control group. The study found that 33.9% of patients receiving durvalumab were alive at 18 months.
A large cohort study confirms that adding transarterial chemoembolization (TACE) to sorafenib improves survival rates in patients with advanced liver cancer, with median overall survival increasing by up to 26%. The treatment combination also shows similar tolerability compared to sorafenib alone.
Researchers identified a drug combination that significantly extends patient survival in lung transplant recipients, offering a potential solution to the median survival rate of less than six years after transplantation. Sirolimus plus tacrolimus was associated with a better median survival than MMF plus tacrolimus.
A study published in Acta Neuropathologica Communications found that interregional differences in the somatic genetic landscape of glioblastoma affect prognosis. The research analyzed Japanese patients with IDH-wildtype GBM and discovered a biomarker, triple CNA, associated with survival duration.
A study by University of Jyväskylä and Luke found that enriched rearing significantly enhances the survival of fish from bacterial infection in aquaculture. The results may advance natural disease prevention methods in aquaculture, improving post-release survival after stocking into the wild.
A study published in JAMA Oncology reports higher than expected five-year survival rates for patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer treated with nivolumab. The treatment showed durable responses and improved outcomes for patients without cancer-related symptoms.
Radiotherapy patients experiencing hurricane disasters had significantly worse overall survival rates than those completing treatment in normal circumstances. Longer disaster declarations were associated with increasingly worse survival outcomes.
Researchers found PRRT to be safe and effective for patients with grade 3 neuroendocrine neoplasms, with a median progression-free survival rate of 9.6 months and overall survival rate of 19.9 months. Patients with low Ki-67 index responded more favorably to PRRT.
A recent study found that only 5.5% of glioblastoma patients survive five years after diagnosis, highlighting the need for more aggressive treatments to improve long-term survival. The research analyzed 48,652 cases and identified factors associated with five-year survival, including age, race, gender, and treatment with radiotherapy.
Despite improvements in cancer treatment for HIV/AIDS-related cancers, adolescents and young adults continue to face disparities in survival rates by race, ethnicity, and socioeconomic status. The study highlights the need for continued research to improve survival rates in this vulnerable age group.
The ECOG-ACRIN Cancer Research Group's phase three trial, E2810, found that pazopanib treatment did not improve disease-free survival in Stage IV patients with no evidence of disease following a surgery to remove the metastases. Average survival for these patients is about two to three years and long-term survival is uncommon.
Researchers at Burrell College of Osteopathic Medicine found that New Mexicans with 10 common cancers have a significantly worse five-year survival rate. Hispanic populations along the U.S.-Mexico border fare even worse.
A recent clinical trial at the Stephenson Cancer Center found that patients with stage two, three, or four ovarian cancer can expect about 75 months of survival when their tumors are completely removed. The treatment regimen that caused fewer difficult side effects was just as effective as those with more severe side effects.
Researchers found that omitting chemotherapy in HER2 positive metastatic breast cancer can significantly shorten progression-free survival but not overall survival. The PERNETTA trial suggests that targeted therapy alone may be safe for patients with low-to-intermediate tumour burden.